BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-08

204 industry Phase 2/3 trial readout(s) and 40 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-07 | 2024-09 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-08-01FDA approvalapprovedGLAXOSMITHKLINEJEMPERLIApproved 2024-08-01: JEMPERLI (BLA761174 SUPPL9)
2024-08-02FDA AdComheldAdCom 2024-08-02: Genetic Metabolic Diseases Advisory Committee
2024-08-06FDA approvalapprovedSERVIERVORANIGOApproved 2024-08-06: VORANIGO (NDA218784 ORIG1)
2024-08-07FDA approvalapprovedNOVARTIS NVSFABHALTAApproved 2024-08-07: FABHALTA (NDA218276 SUPPL1)
2024-08-07FDA approvalapprovedCITIUS PHARMS CTXRLYMPHIRApproved 2024-08-07: LYMPHIR (BLA761312 ORIG1)
2024-08-07FDA approvalapprovedIMPAXCREXONTApproved 2024-08-07: CREXONT (NDA217186 ORIG1)
2024-08-07FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2024-08-07: KEYTRUDA (BLA125514 SUPPL157)
2024-08-07FDA approvalapprovedKNOA PHARMAZURNAI (AUTOINJECTOR)Approved 2024-08-07: ZURNAI (AUTOINJECTOR) (NDA218590 ORIG1)
2024-08-08Complete response lettercomplete responseLykos Therapeuticsthe treatment of posttraumatic stress disorder (PTSD)CRL 2024-08-08: Lykos Therapeutics NDA 215455 (the treatment of posttraumatic stress disorder (PTSD))
2024-08-08FDA approvalapprovedARGENX BVVYVGARTApproved 2024-08-08: VYVGART (BLA761195 SUPPL4)
2024-08-08FDA approvalapprovedARGENX BVVYVGART HYTRULOApproved 2024-08-08: VYVGART HYTRULO (BLA761304 SUPPL3)
2024-08-09FDA approvalapprovedSCPHARMACEUTICALSFUROSCIX FUROSCIX READYFLOWApproved 2024-08-09: FUROSCIX; FUROSCIX READYFLOW (AUTOINJECTOR) (NDA209988 SUPPL1)
2024-08-09FDA approvalapprovedSANDOZ INCENZEEVUApproved 2024-08-09: ENZEEVU (BLA761382 ORIG1)
2024-08-09FDA approvalapprovedARS PHARMS OPERATIONNEFFYApproved 2024-08-09: NEFFY (NDA214697 ORIG1)
2024-08-09FDA approvalapprovedASCENDIS PHARMA BONE ASNDYORVIPATHApproved 2024-08-09: YORVIPATH (NDA216490 ORIG1)
2024-08-10FDA approvalapprovedCENTRAL WELDING SUPPLYCARBON DIOXIDE USPApproved 2024-08-10: CARBON DIOXIDE, USP (NDA219779 ORIG1)
2024-08-12FDA approvalapprovedGALDERMA LABS LPNEMLUVIOApproved 2024-08-12: NEMLUVIO (BLA761390 ORIG1)
2024-08-12FDA approvalapprovedWYETH PHARMSPROTONIX IVApproved 2024-08-12: PROTONIX IV (NDA020988 SUPPL70)
2024-08-14FDA approvalapprovedGILEAD SCIENCES INC GILDLIVDELZIApproved 2024-08-14: LIVDELZI (NDA217899 ORIG1)
2024-08-14FDA approvalapprovedINCYTE CORP INCYNIKTIMVOApproved 2024-08-14: NIKTIMVO (BLA761411 ORIG1)
2024-08-15FDA approvalapprovedMEDIWOUND, LTD MDWDNEXOBRIDApproved 2024-08-15: NEXOBRID (BLA761192 SUPPL10)
2024-08-15FDA approvalapprovedASTRAZENECA UK LTD AZNIMFINZIApproved 2024-08-15: IMFINZI (BLA761069 SUPPL43)
2024-08-16Complete response lettercomplete responseAntares Pharma, Inc.hydrocortisone sodium phosphate injectionCRL 2024-08-16: Antares Pharma, Inc. NDA 218026 (hydrocortisone sodium phosphate injection)
2024-08-19Complete response letterapproved sinceScienture Inc. SCNXlosartan potassium oral suspensionCRL 2024-08-19: Scienture Inc. NDA 218772 (losartan potassium oral suspension)
2024-08-19FDA approvalapprovedJANSSEN BIOTECHRYBREVANTApproved 2024-08-19: RYBREVANT (BLA761210 SUPPL5)
2024-08-19FDA approvalapprovedJANSSEN BIOTECHLAZCLUZEApproved 2024-08-19: LAZCLUZE (NDA219008 ORIG1)
2024-08-20Complete response letterapproved sinceRegeneron Pharmaceuticals, Inc. REGNREGN5458 (linvoseltamab)CRL 2024-08-20: Regeneron Pharmaceuticals, Inc. BLA 761400 (REGN5458 (linvoseltamab))
2024-08-20FDA approvalapprovedAMGEN INC AMGNAMJEVITAApproved 2024-08-20: AMJEVITA (BLA761024 SUPPL19)
2024-08-22FDA approvalapprovedASTRAZENECA AB AZNBEYFORTUSApproved 2024-08-22: BEYFORTUS (BLA761328 SUPPL5)
2024-08-23FDA approvalapprovedAMGEN INC AMGNPAVBLUApproved 2024-08-23: PAVBLU (BLA761298 ORIG1)
2024-08-26FDA approvalapprovedALTHERA PHARMSROSZETApproved 2024-08-26: ROSZET (NDA213072 SUPPL4)
2024-08-26FDA approvalapprovedB BRAUNCEFAZOLIN AND DEXTROSEApproved 2024-08-26: CEFAZOLIN AND DEXTROSE (NDA050779 SUPPL34)
2024-08-26FDA approvalapprovedSHILPABORTEZOMIBApproved 2024-08-26: BORTEZOMIB (NDA212782 ORIG1)
2024-08-28FDA approvalapprovedSCILEX PHARMSGLOPERBAApproved 2024-08-28: GLOPERBA (NDA210942 SUPPL2)
2024-08-30FDA approvalapprovedMERCK SHARP DOHME MRKPREVYMISApproved 2024-08-30: PREVYMIS (NDA209939 SUPPL13)
2024-08-30FDA approvalapprovedMERCK SHARP DOHME MRKPREVYMISApproved 2024-08-30: PREVYMIS (NDA209939 SUPPL16)
2024-08-30FDA approvalapprovedMERCK SHARP DOHME MRKPREVYMISApproved 2024-08-30: PREVYMIS (NDA209940 SUPPL16)
2024-08-30FDA approvalapprovedMERCK SHARP DOHME MRKPREVYMISApproved 2024-08-30: PREVYMIS (NDA209940 SUPPL12)
2024-08-30FDA approvalapprovedBRISTOL BMYZEPOSIAApproved 2024-08-30: ZEPOSIA (NDA209899 SUPPL11)
2024-08-30FDA approvalapprovedMSDPREVYMISApproved 2024-08-30: PREVYMIS (NDA219104 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-08 est.P1/P2Talaris Therapeutics Inc.NCT00498160 Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell InfusionRenal Failureunknown38
2024-08P3Candel Therapeutics, Inc. CADLNCT01436968 Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerProstate Canceractive not recruiting711
2024-08 est.P2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04826107 Study of DP303c Injection in Patients With Advanced or Metastatic Gastric CancerGastric Cancerunknown196
2024-08 est.P2Valo Health, Inc.NCT05327855 Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)Myocardial Infarctionwithdrawn
2024-08 est.P2Valo Health, Inc.NCT05393284 Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic RetinopathyNon-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathyunknown114
2024-08 est.P2Ellipses PharmaNCT05411679 EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung CancerGastric Cancer; Small-cell Lung Cancerwithdrawn
2024-08 est.P1/P2Eledon Pharmaceuticals ELDNNCT05480657 Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1DBrittle Type 1 Diabetes Mellituswithdrawn
2024-08 est.P3Connect Biopharm LLC CNTBNCT05614817 CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic DermatitisAtopic Dermatitiswithdrawn
2024-08 est.P3Laboratorio Elea Phoenix S.A.NCT05668650 Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLCNon Small Cell Lung Cancer Metastaticunknown174
2024-08 est.P1/P2Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.NCT05728619 HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung CancerRecurrent Extensive Stage Small Cell Lung Carcinomaunknown64
2024-08 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05783921 A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line TRecurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Squamous Cell Carcinomaunknown60
2024-08 est.P3Marinus PharmaceuticalsNCT05814523 To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)Refractory Status Epilepticuswithdrawn
2024-08 est.P3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05862337 Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.Hepatocellular Carcinomarecruiting480
2024-08 est.P2Constant Therapeutics LLCNCT06013839 TXA127 in Non-Ambulant Patients With DMD CardiomyopathyDMD-Associated Dilated Cardiomyopathyunknown10
2024-08 est.P1/P2Biocity Biopharmaceutics Co., Ltd.NCT06111326 BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular CarcinomaHepatocellular Carcinomaunknown83
2024-08 est.P2Glaukos Corporation GKOSNCT06152861 Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular HypertensionOpen Angle Glaucoma; Ocular Hypertensionunknown250
2024-08-01 est.P2Promontory Therapeutics Inc.NCT02266745 A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Advanced Solid Tumors; CRPC; mCRPC; Metastatic Castrate-resistant Prostate Cancer; PT-112; Prostaticunknown109
2024-08-01P1/P2Taiho Oncology, Inc.NCT03520075 Study of ASTX029 in Subjects With Advanced Solid TumorsSolid Tumor, Adultcompleted192
2024-08-01P2Ascentage Pharma Group Inc. AAPGNCT04126681 A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseChronic Myeloid Leukemia, Chronic Phasecompleted144
2024-08-01P3Sanofi SNYNCT04180488 Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, IntoleChronic Spontaneous Urticariacompleted397
2024-08-01 est.P2Celltex Therapeutics CorporationNCT04448106 Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for OsteoarthritisOsteoarthritis, Knee; Osteoarthritis, Hip; Osteoarthritis Shoulderunknown300
2024-08-01P2Cereno Scientific ABNCT05224531 Effect of CS1 in Subjects With Pulmonary Arterial HypertensionPulmonary Arterial Hypertensioncompleted25
2024-08-01P1/P2Anaveon AGNCT05578872 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).Melanoma (Skin); Cutaneous Melanoma; Adult Disease; Advanced Solid Tumor; Metastatic Melanomacompleted29
2024-08-01P2/P3Boehringer IngelheimNCT05819398 Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis SuppurativaHidradenitis Suppurativacompleted209
2024-08-01P2Otsuka Beijing Research InstituteNCT05923892 Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea TypeIrritable Bowel Syndrome of Diarrhea Type (IBS-D)completed87
2024-08-01P2Arbutus Biopharma Corporation ABUSNCT06245291 Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV InfectionHepatitis B, Chronicwithdrawn
2024-08-01 est.P2JKT Biopharma Co., Ltd.NCT06288893 SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)COVID-19unknown30
2024-08-02P3GE HealthcareNCT04265209 [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential TremorParkinson Disease; Essential Tremorcompleted152
2024-08-02P3Curium US LLCNCT05204927 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate CancerMetastasis From Malignant Tumor of Prostateactive not recruiting439
2024-08-02 est.P1/P2Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdNCT05381662 CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation TreatmentAcute Lymphoblastic Leukemia in Remissionunknown10
2024-08-02P3Corxel PharmaceuticalsNCT05410860 Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular TachycardiaTachycardia, Supraventricular; Paroxysmal Supraventricular Tachycardiacompleted500
2024-08-02P2Novartis Pharmaceuticals NVSNCT05462990 A Proof-of-concept Study to Examine QUC398 in Participants With Knee OAOsteoarthritis, Kneeterminated101
2024-08-02P2GH Research Ireland LimitedNCT05804708 Phase 2 Clinical Trial of GH001 in Postpartum DepressionPostpartum Depression; Postnatal Depressionterminated10
2024-08-05P2Janssen Research & Development, LLCNCT03842189 A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe HemolHemolytic Disease of the Fetus and Newborncompleted25
2024-08-05P2MedPacto, Inc.NCT04515979 Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) SubjectsCarcinoma, Non-Small-Cell Lungterminated11
2024-08-05P3AstraZeneca AZNNCT04924608 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasNeurofibromatosis 1; Plexiform Neurofibroma (PN)active not recruiting145
2024-08-05P3GlaxoSmithKlineNCT04937387 Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaAsthmacompleted359
2024-08-05P3Novo Nordisk A/S NVONCT05330325 A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to GrowSGA, Turner Syndrome, Noonan Syndrome, ISSactive not recruiting412
2024-08-05P3Insud PharmaNCT05461573 Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in FemalesContraception; Change in Bone Mineral Densitycompleted1542
2024-08-05P3Takeda TAKNCT05529992 A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseGaucher Diseasecompleted20
2024-08-05P2/P3Advagene Biopharma Co. Ltd.NCT05541510 Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19COVID-19terminated180
2024-08-05P2argenx ARGXNCT05810961 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)Membranous Nephropathyterminated8
2024-08-05P2/P3Laurent Pharmaceuticals Inc.NCT05999435 Study of LAU-7b for the Treatment of Long COVID in AdultsLong COVIDcompleted272
2024-08-05P2Beijing InnoCare Pharma Tech Co., Ltd.NCT06109818 Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque PsoriasisModerate to Severe Plaque Psoriasiscompleted129
2024-08-05P3Colgate Palmolive CLNCT06427499 The Clinical of Stannous Fluoride Toothpaste and a Newly Designed Toothbrush Compared to Colgate Cavity Protection Toothpaste and a Regular Toothbrush in ReduciPlaque; Gingivitiscompleted95
2024-08-05P1/P2PT. JES Kasih Nusantara SejahterahNCT06866158 Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney DiseaseDiabetic Kidney Disease (DKD)active not recruiting80
2024-08-06P3AstraZeneca AZNNCT04157335 Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)Nasal Polyposis; Eosinophilic Chronic Rhinosinusitisterminated295
2024-08-06P2UCB Biopharma SRLNCT04519645 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal SeizuresElectroencephalographic Neonatal Seizures; Epilepsyterminated29
2024-08-06P2Imbria Pharmaceuticals, Inc.NCT04826159 IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)Type 2 Diabetes; Diabetic Cardiomyopathies; HFpEF - Heart Failure With Preserved Ejection Fractioncompleted49
2024-08-06P2Tempus AI TEMNCT05169437 Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsSolid Tumor; Breast Tumor; Colon Tumor, Malignant; Lung Tumor; Urologic Cancer; Pancreatic Cancer; Mterminated22
2024-08-06P2Bristol-Myers Squibb BMYNCT05730725 A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe PsoriasisPsoriasiscompleted109
2024-08-06P2AbbVie ABBVNCT05771428 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild AAlzheimer's Disease (AD)completed263
2024-08-07P1/P2BioMarin Pharmaceutical BMRNNCT03520712 Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5Hemophilia A; Gene Therapy; Clotting Disorders; Blood Disorderterminated3
2024-08-07P3Novartis Pharmaceuticals NVSNCT04873934 Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary SyndromeAcute Coronary Syndromecompleted400
2024-08-07P2Guangdong Hengrui Pharmaceutical Co., LtdNCT05722964 Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosiscompleted30
2024-08-07P3Kowa Company, Ltd.NCT05923281 A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin IntoleranceHypercholesterolemiacompleted71
2024-08-07P3R-PharmNCT06320353 Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin MelanomaSkin Melanomacompleted266
2024-08-08P2Novartis Pharmaceuticals NVSNCT04097379 Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OAOsteoarthritis (OA)completed45
2024-08-08P3GlaxoSmithKlineNCT04133909 Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelPulmonary Disease, Chronic Obstructivecompleted806
2024-08-08P3Aerovate TherapeuticsNCT05557942 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)Pulmonary Arterial Hypertensionterminated186
2024-08-08P3Ionis Pharmaceuticals, Inc. IONSNCT05610280 A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe HypertriglyceridemiaHypertriglyceridemia; Cardiovascular Diseases; Atherosclerosiscompleted1478
2024-08-08P2InSilico Medicine Hong Kong LimitedNCT05938920 Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)completed71
2024-08-08P2Bristol-Myers Squibb BMYNCT06094296 A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NSCLCterminated1
2024-08-09P2Ascletis Pharmaceuticals Co., Ltd.NCT04465890 A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B PatientsChronic Hepatitis bcompleted207
2024-08-09P2/P3Aerovate TherapeuticsNCT05036135 A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertensionterminated202
2024-08-09P1/P2Nanjing Leads Biolabs Co.,LtdNCT05223231 Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant TumorsAdvanced Malignant Tumorscompleted26
2024-08-09 est.P2Hrain Biotechnology Co., Ltd.NCT05436223 Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's LymphomaB-cell Non-Hodgkin's Lymphomaunknown100
2024-08-09P2/P3Ascendis Pharma Growth Disorders A/S ASNDNCT05598320 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With AchondroplasiaAchondroplasiacompleted84
2024-08-09P3Eli Lilly and Company LLYNCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitis; Ulcerative Colitis Chroniccompleted172
2024-08-09P2Dexa Medica GroupNCT06127225 Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD)Non-Alcoholic Fatty Liver Disease (NAFLD)completed80
2024-08-09P2/P3Chengdu Suncadia Medicine Co., Ltd.NCT07844356 The Safety and Efficacy of HR19034 in Children With MyopiaSlowing the Progression of Myopia in Childrencompleted509
2024-08-11P2Hunazine Biotech S.L.NCT06193408 Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in CholeraCholeracompleted150
2024-08-12P3Pharmicell Co., Ltd.NCT01652209 To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.Acute Myocardial Infarctioncompleted90
2024-08-12P3Biogen BIIBNCT03070119 Long-Term Evaluation of BIIB067 (Tofersen)ALS Caused by Superoxide Dismutase 1 (SOD1) Mutationcompleted139
2024-08-12P2Hanmi Pharmaceutical Company Limited HAFCNCT04768686 FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric CancerGastric Cancercompleted20
2024-08-12P2Syros PharmaceuticalsNCT04905407 Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)Acute Myeloid Leukemiaterminated66
2024-08-12P1/P2Ascentage Pharma Group Inc. AAPGNCT04946864 A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerBreast Cancer; Solid Tumor, Adultsuspended65
2024-08-12P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05179239 A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical CancerCervical Cancerterminated31
2024-08-12P3Biogen BIIBNCT05310071 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseAlzheimer's Diseaseterminated1027
2024-08-12P2AstraZeneca AZNNCT05492877 An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.Chronic Obstructive Pulmonary Disease (COPD)completed381
2024-08-12P2Bristol-Myers Squibb BMYNCT05577715 A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)Carcinoma, Non-Small-Cell Lungterminated31
2024-08-12P1/P2Pfizer PFENCT05626322 Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaDiffuse Large B-Cell Lymphomaterminated6
2024-08-12P3Ellodi Pharmaceuticals, LPNCT05634746 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)Eosinophilic Esophagitiscompleted218
2024-08-12P2GlaxoSmithKlineNCT05838742 A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) PainPain; Osteoarthritis, Kneeterminated314
2024-08-12P2Oneness Biotech Co., Ltd.NCT05941793 A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 PatientsMild to Moderate COVID-19completed135
2024-08-12P2Prolacta BioscienceNCT06102213 Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell TransplantationHematologic Malignancyterminated46
2024-08-13P3Hoffmann-La RocheNCT04487067 A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma NoCarcinoma, Hepatocellularcompleted152
2024-08-13P1/P2Biogen BIIBNCT04494256 A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and ParticipanAmyotrophic Lateral Sclerosisterminated99
2024-08-13P2Novartis Pharmaceuticals NVSNCT04546633 Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated PUncomplicated Plasmodium Falciparum Malariacompleted295
2024-08-13P3Novartis Pharmaceuticals NVSNCT04935359 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Metastatic Pancreatic Ductal Adenocarcinomacompleted511
2024-08-13P2TBF Genie TissulaireNCT05199155 Use of a Nerve Regeneration Conduit (NerVFIX®) in the Treatment of Nerve Section of the WristNerve Injury; Nerve Lesionterminated12
2024-08-13P2Arthrosi TherapeuticsNCT05253833 Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous GoutGout; Arthritis, Gouty; Hyperuricemia; Gout Chroniccompleted42
2024-08-13P2Alumis Inc ALMSNCT05953688 POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUUveitis Posterior Non-Infectious; Uveitis, Intermediate; Noninfectious Panuveitisterminated36
2024-08-13P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06118021 A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsOverweight and Obesitycompleted200
2024-08-13P3Jiangsu HengRui Medicine Co., Ltd.NCT06222294 A Study of Remimazolam Tosilate for Sedation in the ICUSedation in the ICUcompleted214
2024-08-13P2Regor Pharmaceuticals Inc.NCT06277934 A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related ComorbiditiesObesitycompleted73
2024-08-13P2G.ST Antivirals GmbHNCT06375772 A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy AdultsAcute Nasopharyngitisterminated64
2024-08-13P2BrightGene Bio-Medical Technology Co., Ltd.NCT06974825 A Study of BGM0504 in Chinese Patients With Type 2 DiabetesType 2 Diabetescompleted67
2024-08-14P3Novartis Pharmaceuticals NVSNCT06149104 A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed Heart Failurecompleted8
2024-08-14P3Takeda TAKNCT06422377 A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to FenfluramineDravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS)terminated1
2024-08-15P3Hoffmann-La RocheNCT04221477 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisLupus Nephritisactive not recruiting271
2024-08-15P3Eisai Inc.NCT04572243 A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeEpilepsies, Myoclonicterminated22
2024-08-15P1/P2Incyte Corporation INCYNCT04582539 To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple MyelomaMyelodysplastic Syndromes; Multiple Myeloma; Anemiaterminated22
2024-08-15 est.P3AO GENERIUMNCT04667039 Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®Age Related Macular Degeneration (ARMD)unknown408
2024-08-15P3Merck Sharp & Dohme LLC MRKNCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal CaColorectal Cancercompleted441
2024-08-15P2AbbVie ABBVNCT05227703 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaSchizophreniacompleted391
2024-08-15P3Grünenthal GmbHNCT05449132 Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the KneeOsteoarthritiscompleted466
2024-08-15P1/P2Hoffmann-La RocheNCT05459129 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (MorpheSquamous Cell Carcinoma of the Head and Neckcompleted12
2024-08-15P3Merck Sharp & Dohme LLC MRKNCT05600309 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal CaColorectal Cancercompleted94
2024-08-15P2argenx ARGXNCT05918978 Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTSPost-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrometerminated33
2024-08-15P2/P3Kendal Nutricare LtdNCT06312059 Goat or Cow Milk Based Infant Formula GMSGrowthcompleted409
2024-08-16P3Boehringer IngelheimNCT05321069 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosiscompleted1177
2024-08-16P3Sunshine Lake Pharma Co., Ltd. SBFMNCT05802862 A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in ChiDiabetescompleted414
2024-08-18 est.P2MimiVax, LLCNCT05163080 SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)Newly Diagnosed Glioblastomaunknown247
2024-08-18P2Navitor Pharmaceuticals, Inc.NCT06235905 Open-Label of SPN-820 in Adults With Major Depressive DisorderMajor Depressive Disordercompleted40
2024-08-19P2Novartis Pharmaceuticals NVSNCT04541589 Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's SyndromeSjogren's Syndromecompleted206
2024-08-19P2Alector Inc. ALECNCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseAlzheimer Diseasecompleted356
2024-08-19P2Enanta Pharmaceuticals, Inc ENTANCT04816721 A Study to Evaluate EDP 938 Regimens in Children With RSVRespiratory Syncytial Virus (RSV)completed99
2024-08-19P2GlaxoSmithKlineNCT05064358 Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple MyelomaMultiple Myelomacompleted177
2024-08-19P2Bristol-Myers Squibb BMYNCT05556343 A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, Hypertrophicterminated18
2024-08-19P2Vertex Pharmaceuticals Incorporated VERXNCT05643495 A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ GenotypeAlpha-1 Antitrypsin Deficiencyterminated14
2024-08-19P2Kainos Medicine Inc.NCT05695378 Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)Multiple System Atrophyterminated68
2024-08-19P3Novo Nordisk A/S NVONCT05891496 A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's DiseaseAlzheimers Diseasecompleted23
2024-08-19P1/P2Janssen Vaccines & Prevention B.V.NCT05901636 A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy AdultsInfluenza Preventioncompleted170
2024-08-19P3Corxel PharmaceuticalsNCT06045299 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the PresbyopiaPresbyopia; Near Vision; Miosis; Eye Diseasescompleted300
2024-08-19P3AkesoNCT06066125 A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque PsoriasisPsoriasis; Skin Diseasescompleted351
2024-08-19P2Aligos Therapeutics ALGSNCT06342947 ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)NASH; MASH; Metabolic Dysfunction-Associated Steatohepatitis; Nonalcoholic Steatohepatitiscompleted102
2024-08-20P1/P2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT04735575 A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaRelapsed or Refractory Multiple Myelomaterminated40
2024-08-20P2Inversago Pharma Inc.NCT05514548 Phase 2 Study of INV-202 in Patients With Diabetic Kidney DiseaseDiabetic Kidney Diseasecompleted265
2024-08-20P2BayerNCT05526248 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been TBiochemically Recurrent Prostate Cancercompleted28
2024-08-20P3IpsenNCT05590793 Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the ProstateAdvanced Prostate Cancer; Metastatic Prostate Cancer; Locally Advanced Prostate Cancercompleted195
2024-08-20P1/P2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT05794477 A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid TumorsAdvanced Solid Tumorcompleted16
2024-08-20P2Clearside Biomedical, Inc.NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular DegenerationNeovascular Age-related Macular Degenerationcompleted60
2024-08-20P2Qlaris Bio, Inc.NCT06016972 Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT PatientsPrimary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Glacompleted63
2024-08-21P3Gilead Sciences GILDNCT04925752 Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV InfectionPre-Exposure Prophylaxis of HIV Infectionactive not recruiting3292
2024-08-21P3Kissei Pharmaceutical Co., Ltd.NCT05440383 A Clinical Study of KLH-2109 in Uterine Fibroids Patient With MenorrhagiaUterine Fibroids (MeSH Heading: Leiomyoma)completed287
2024-08-22P1/P2Amicus TherapeuticsNCT02675465 First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221Pompe Diseasecompleted29
2024-08-22P1/P2Bristol-Myers Squibb BMYNCT04349267 Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsAdvanced Solid Tumorcompleted44
2024-08-22P1/P2Novartis Pharmaceuticals NVSNCT04623216 Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.Acute Myeloid Leukemiaterminated24
2024-08-22P2Bristol-Myers Squibb BMYNCT04857034 A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)Lupus Erythematosus, Discoid; Lupus Erythematosus, Subacute Cutaneousactive not recruiting74
2024-08-22P3Apollomics Inc. APLMNCT05054543 Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AMLRelapsed/Refractory AMLterminated140
2024-08-22P2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT05223920 An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)Thrombocythemia, Essential; Primary Myelofibrosiscompleted81
2024-08-22P1/P2Bristol-Myers Squibb BMYNCT05407675 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Advanced Solid Tumorscompleted68
2024-08-22P3Bond Avillion 2 Development LPNCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With AsthmaAsthmacompleted2516
2024-08-22P2Invirsa, Inc.NCT05636228 Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious KeratoconjunctivitisAcute Infectious Keratoconjunctivitiscompleted93
2024-08-22P2Sanofi SNYNCT05849922 A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis SuppurativaHidradenitis Suppurativacompleted86
2024-08-22P2BayerNCT06112756 A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With MenopauseSleep Disturbances Associated With Menopausecompleted110
2024-08-23P2AstraZeneca AZNNCT03778229 Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibCarcinomaactive not recruiting367
2024-08-23P3Novo Nordisk A/S NVONCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2completed9651
2024-08-23P3Janssen Pharmaceutical K.K.NCT05167825 A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial HypertensionPulmonary Arterial Hypertensioncompleted7
2024-08-23P2AbbVie ABBVNCT05227690 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaSchizophreniacompleted385
2024-08-23P3Jadran Galenski laboratorij d.d.NCT07050446 Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry EyeDry Eye Disease (DED)completed86
2024-08-24P3Viatris Specialty LLC VTRSNCT06215820 Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following BunionectomyAcute Pain; Post Operative Pain; Paincompleted410
2024-08-25P3Colgate Palmolive CLNCT06430060 Investigation of Colgate Dual Zinc Toothpaste as Compared to Colgate Cavity Protection Toothpaste in Controlling Plaque and GingivitisPlaque, Dental; Gingivitiscompleted86
2024-08-26P2Pfizer PFENCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsEwing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffucompleted128
2024-08-26P3Merck Sharp & Dohme LLC MRKNCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated AOvarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasmscompleted1367
2024-08-26P3Antengene CorporationNCT04939142 A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With RelapsedRelapsed or Refractory Multiple Myelomacompleted154
2024-08-26P2Genome & CompanyNCT05419362 GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric CancerGastric Cancer; Gastroesophageal Junction Adenocarcinomacompleted42
2024-08-26P2Novartis Pharmaceuticals NVSNCT05497284 To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPFIdiopathic Pulmonary Fibrosisterminated46
2024-08-26P3Novartis Pharmaceuticals NVSNCT05513001 An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies WithChronic Spontaneous Urticariaactive not recruiting696
2024-08-26P2Adverum Biotechnologies, Inc.NCT05536973 Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Neovascular Age-related Macular Degenerationactive not recruiting69
2024-08-26P3Amgen AMGNNCT05899816 A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)Atopic Dermatitis; Moderate-to-severe Atopic Dermatitiscompleted221
2024-08-26P1/P2EyeBiotech Ltd.NCT05919693 A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT)Neovascular Age-related Macular Degeneration (NVAMD); Diabetic Macular Edema (DME)completed33
2024-08-26P2Hope Medicine (Nanjing) Co., LtdNCT06118866 A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic AlopeciaAndrogenetic Alopeciacompleted192
2024-08-27P1/P2X4 Pharmaceuticals XFORNCT04154488 A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia DisordersNeutropeniacompleted32
2024-08-27P3OctapharmaNCT04508530 Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)Pediatric Acute-Onset Neuropsychiatric Syndromecompleted71
2024-08-27P3EMD Serono Research & Development Institute, Inc.NCT05386550 Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)Head and Neck Cancerterminated166
2024-08-27P3Valneva Austria GmbHNCT06028841 A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)Chikungunya Virus Infectionwithdrawn
2024-08-27P2ViiV HealthcareNCT06061081 A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1HIV Infectionsterminated21
2024-08-28P3ActelionNCT02932410 A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertensioncompleted165
2024-08-28P3Bristol-Myers Squibb BMYNCT04008030 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/MMetastatic Colorectal Canceractive not recruiting839
2024-08-28P1/P2BeiGeneNCT04282018 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and TislelizumabChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Follicular Lymphoma; Marginal Zone Lymphomcompleted97
2024-08-28P2NeoImmuneTechNCT04984811 NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLCCarcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall terminated33
2024-08-29P1/P2Bristol-Myers Squibb BMYNCT03446040 An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadAdvanced Cancerterminated92
2024-08-29P1/P2Nerviano Medical SciencesNCT03922100 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMMLAcute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia (CMML)terminated63
2024-08-29P3Sanofi SNYNCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)Non-relapsing Secondary Progressive Multiple Sclerosiscompleted1131
2024-08-29P2PTC Therapeutics PTCNCT05485987 A Study of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaFriedreich Ataxiacompleted5
2024-08-29P2D. Western Therapeutics Institute, Inc.NCT05913232 Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionGlaucoma Open-Angle Primary; Ocular Hypertensioncompleted201
2024-08-29P2/P3Xgene Pharmaceutical GroupNCT06017999 XG005 for Pain Control in Subjects Undergoing BunionectomyAcute Paincompleted450
2024-08-29P2Janssen Research & Development, LLCNCT06028438 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid ArthritisArthritis, Rheumatoidcompleted103
2024-08-30P3Bristol-Myers Squibb BMYNCT03036098 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of ParticipaUrothelial Cancercompleted1314
2024-08-30P3EMSNCT03527069 Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia TreatmentHypertriglyceridemia; Dyslipidemiacompleted146
2024-08-30 est.P3Nanjing Yoko Biomedical Co., Ltd.NCT04205565 Study on Clinical Effectiveness of L-Oxiracetam InjectionCraniocerebral Injuryunknown591
2024-08-30P1/P2Arcus Biosciences, Inc. RCUSNCT04381832 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerProstatic Neoplasms, Castration-Resistant; Androgen-Resistant Prostatic Neoplasms; Castration Resistcompleted173
2024-08-30P1/P2BeiGeneNCT05267054 Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabRelapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphomacompleted53
2024-08-30 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05324631 A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial SpondyloarthritisNon-radiographic Axial Spondyloarthritisunknown300
2024-08-30P3ShionogiNCT05897541 Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 InfectionSARS-CoV-2 Infectioncompleted3701
2024-08-30P3Zensun Sci. & Tech. Co., Ltd.NCT05949801 Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart FailureChronic Systolic Heart Failurecompleted202
2024-08-30P2GlaxoSmithKlineNCT05960097 A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy AdultsSARS-CoV-2; COVID-19completed692
2024-08-30 est.P1/P2QureBio Ltd.NCT05964543 The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal TumorsGastroesophageal Junction (GEJ) Adenocarcinomaunknown72
2024-08-30P1/P2GPN VaccinesNCT05982314 Extension Safety and Immunogenicity Study of GPNV-001Pneumococcal Infectionscompleted60
2024-08-30 est.P3Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06314685 Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 YearsHealthy Populationunknown2450
2024-08-30P2Ebima Clifford OkundayeNCT06948292 Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients ClinicsChronic Kidney Disease Stages 3-5; Diabetic Kidney Disease; Hypertensive Kidney Diseasecompleted127
2024-08-31P1/P2Karyopharm Therapeutics Inc KPTIQNCT02649790 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsRelapsed/Refractory Multiple Myeloma (RRMM); Metastatic Colorectal Cancer (mCRC); Metastatic Castratcompleted277
2024-08-31P1/P2Bristol-Myers Squibb BMYNCT03994601 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersAdvanced Cancercompleted219
2024-08-31P3Sanofi Pasteur, a Sanofi Company SNYNCT04904549 Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and OlderCOVID-19terminated23670
2024-08-31 est.P2Neurokine TherapeuticsNCT05194163 MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's DiseaseAlzheimer Diseaseunknown24
2024-08-31P1/P2TransThera Sciences (Nanjing), Inc.NCT05253053 To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsAdvanced Solid Tumor; Cholangiocarcinoma; Biliary Tract Cancer; HER2-negative Breast Cancer; Triple completed84
2024-08-31P2SOTIO Biotech AGNCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsNon-Small Cell Lung Cancer; Colorectal Cancer; Cutaneous Squamous Cell Carcinoma; Hepatocellular Carterminated166
2024-08-31 est.P2Orthocare Innovations, LLCNCT05619484 Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFOStrokeunknown50
2024-08-31 est.P2Clairvoyant TherapeuticsNCT05646303 Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)Alcohol Use Disorderunknown128
2024-08-31P1/P2InxMed (Shanghai) Co., Ltd.NCT05830539 IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor PatientsLocally Advanced or Metastatic Solid Tumorscompleted68
2024-08-31 est.P1/P2Luye Pharma Group Ltd.NCT05865925 Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid TumorsAdvanced Solid Tumorsunknown78
2024-08-31P2PT Bio FarmaNCT05933278 Homologous Booster Study of COVID-19 Protein Subunit Recombinant VaccineCOVID-19completed150

← 2024-07 | 2024-09 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.